Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 223Y9 | — |
Infanrix administration instead of Boostrix; Infanrix out of the recommended age administration/Infanrix administration instead of Boostrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 15-year-old female patient who received DTPa (Infanrix) (batch number 223Y9, expiry date 07-SEP-2026) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 23-JUN-2025, the patient received Infanrix. On an unknown date, the patient did not receive Boostrix. On 23-JUN-2025, an unknown time after receiving Infanrix, the patient experienced wrong vaccine administered (Verbatim: Infanrix administration instead of Boostrix) and adult use of a child product (Verbatim: Infanrix out of the recommended age administration/Infanrix administration instead of Boostrix). The outcome of the wrong vaccine administered and adult use of a child product were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JUN-2025 The Vaccine Administration Facility was the same as Primary Reporter. The Health Care Provider wanted to know how to proceed after a 15 year old patient received Infanrix instead of Boostrix as a second dose in the immunization schedule which led to wrong vaccine administered and adult use of a child product.